Homo sapiens
isolate
GIAB HG008
age
61
biomaterial_provider
Massachusetts General Hospital (MGH)
collection_date
2020-12-30
geo_loc_name
USA
sex
female
tissue
Pancreatic Ductal Adenocarcinoma Cell Line (PDAC)
cell_line
HG008-T
cell_subtype
epithelial-like
cell_type
pancreatic ductal adenocarcinoma
disease
pancreatic ductal adenocarcinoma
disease_stage
tumor stage ypT2 N1, histological grade G2 (Moderately differentiated)
sample_type
cell culture
treatment
neoadjuvant therapy, tumor regression grade 2 (Minimal response: Residual cancer outgrown by fibrosis)
super_population_code
EUR
super_population_description
European
is_tumor
yes
isolation_source
pancreatic ductal adenocarcinoma
passage_history
The individual (known as GIAB HG008) was explicitly consented for tissue collection and public genomic data sharing following a Massachusetts General Hospital (MGH) IRB-approved protocol. The Liss laboratory at MGH established a PDAC tumor cell line (HG008-T) from the resected PDAC tumor. PDAC tumors are stromal-rich, with cancer cells often only composing 10% of the tumor. The cell line was developed starting with approximately 50 mg of tumor tissue being enzymatically dissociated to culture tumor cells. While PDAC cell cultures often contain substantial fibroblasts, all cells appeared to be tumor cells even at passage 2 for this cell line. Cells were cultured for the first 20 passages using "Rich" media composed of DMEM/F12 with 20% Fetal Bovine Serum (FBS) Nicotinamide (0.01 M), cholera toxin (8.4 ng/ml), Epidermal Growth Factor (EGF; 10 ng/ml), Hepatocyte Growth Factor (HGF: 25 ng/ml), human recombinant insulin (10 ug/ml), human recombinant transferrin (5.5 ug/ml), and selenious acid (6.7 ng/ml). Morphologically pure cancer cell cultures, free of tumor-associated fibroblasts, were considered cell lines after growing for at least 20 passages. Passages 21-24 were grown in the same media as prior passages however without EGF. From passage 25 on, the established cell line was then cultured in DMEM/F12 with 10% FBS. All media contained 1% antibiotic/antimycotic. The Liss laboratory transferred cryopreserved viable cells from passages 13 and 29 to NIST in May 2024.
passage_method
Passage 13 cells obtained from the Liss laboratory at MGH were thawed at 37C and washed once with DMEM/F12 medium (Thermo Fisher Scientific) with 10% FBS (Thermo Fisher Scientific). The cells were resuspended in 10 mL DMEM/F12 medium with 10% FBS and plated in a 10 cm dish. When the cells grew up to 90-95% confluent, the cells were washed with PBS once and then enzymatically removed from the culture surface using 0.25% trypsin and split by diluting no more than 1:3 for the first 20 passages. Passages 21 - 38 were generally split 1:3, with some split 1:4 depending on the cell count of each experiment. This Biosample is for measurements from NIST passage 21.
passage_number
NIST_2024p21
BioSampleModel
Human